WO2007017892A3 - Novel compounds as glp-i agonists - Google Patents
Novel compounds as glp-i agonists Download PDFInfo
- Publication number
- WO2007017892A3 WO2007017892A3 PCT/IN2006/000154 IN2006000154W WO2007017892A3 WO 2007017892 A3 WO2007017892 A3 WO 2007017892A3 IN 2006000154 W IN2006000154 W IN 2006000154W WO 2007017892 A3 WO2007017892 A3 WO 2007017892A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glp
- agonists
- novel compounds
- compounds
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002606894A CA2606894A1 (en) | 2005-05-05 | 2006-05-04 | Novel compounds as glp-i agonists |
EA200702419A EA200702419A1 (en) | 2005-05-05 | 2006-05-04 | NEW CONNECTIONS AS GLP-1 AGONISTS |
MX2007013655A MX2007013655A (en) | 2005-05-05 | 2006-05-04 | Novel compounds as glp-i agonists. |
EP06809915A EP1891106A2 (en) | 2005-05-05 | 2006-05-04 | Novel compounds as glp-i agonists |
JP2008509578A JP2008540402A (en) | 2005-05-05 | 2006-05-04 | Novel compounds as GLP-1 agonists |
AP2007004227A AP2007004227A0 (en) | 2005-05-05 | 2006-05-04 | Novel compounds as GLP-1 agonists |
BRPI0612471A BRPI0612471A2 (en) | 2005-05-05 | 2006-05-04 | new compounds as glp-1 agonists |
AU2006277557A AU2006277557A1 (en) | 2005-05-05 | 2006-05-04 | Novel compounds as GPL-I agonists |
IL187105A IL187105A0 (en) | 2005-05-05 | 2007-11-01 | Novel compunds as glp-i agonists |
NO20075618A NO20075618L (en) | 2005-05-05 | 2007-11-06 | Novel compounds as GLP-1 Agonists |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN558/MUM/2005 | 2005-05-05 | ||
IN558MU2005 | 2005-05-05 | ||
IN645MU2005 | 2005-05-31 | ||
IN645/MUM/2005 | 2005-05-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007017892A2 WO2007017892A2 (en) | 2007-02-15 |
WO2007017892A3 true WO2007017892A3 (en) | 2007-09-20 |
Family
ID=37727716
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2006/000154 WO2007017892A2 (en) | 2005-05-05 | 2006-05-04 | Novel compounds as glp-i agonists |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1891106A2 (en) |
JP (1) | JP2008540402A (en) |
KR (1) | KR20080021636A (en) |
AP (1) | AP2007004227A0 (en) |
AU (1) | AU2006277557A1 (en) |
BR (1) | BRPI0612471A2 (en) |
CA (1) | CA2606894A1 (en) |
EA (1) | EA200702419A1 (en) |
IL (1) | IL187105A0 (en) |
MX (1) | MX2007013655A (en) |
NO (1) | NO20075618L (en) |
WO (1) | WO2007017892A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
EP2021014A1 (en) | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
NZ576023A (en) * | 2006-10-03 | 2012-06-29 | Cadila Healthcare Ltd | Antidiabetic compounds comprising a fragment of a glucagon peptide and derivatives thereof |
KR101277560B1 (en) | 2007-12-11 | 2013-06-25 | 카딜라 핼쓰캐어 리미티드 | Peptidomimetics with glucagon antagonistic and GLP-1 agonistic activities |
CN101903400B (en) * | 2007-12-11 | 2013-12-18 | 霍夫曼-拉罗奇有限公司 | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
CA2759468A1 (en) * | 2009-05-01 | 2010-11-04 | F. Hoffmann-La Roche Ag | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
CN101891823B (en) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | Exendin-4 and analog fusion protein thereof |
EP2956160B1 (en) * | 2013-02-15 | 2018-04-25 | Mayo Foundation For Medical Education And Research | Insulin secreting polypeptides |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
WO2002028438A1 (en) * | 2000-10-05 | 2002-04-11 | King's College London | Lipopeptides as absorption enhancers for bioactive compounds |
WO2003011892A2 (en) * | 2001-07-31 | 2003-02-13 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1 exendin-4 peptide analogs and uses thereof |
WO2003058203A2 (en) * | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
WO2004094461A2 (en) * | 2003-04-21 | 2004-11-04 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
WO2005077072A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2006014287A1 (en) * | 2004-07-02 | 2006-02-09 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
WO2006024275A2 (en) * | 2004-09-03 | 2006-03-09 | Philipps-Universität Marburg | Glp-1 and exendin related invention |
-
2006
- 2006-05-04 AU AU2006277557A patent/AU2006277557A1/en not_active Abandoned
- 2006-05-04 MX MX2007013655A patent/MX2007013655A/en not_active Application Discontinuation
- 2006-05-04 EP EP06809915A patent/EP1891106A2/en not_active Withdrawn
- 2006-05-04 WO PCT/IN2006/000154 patent/WO2007017892A2/en active Application Filing
- 2006-05-04 EA EA200702419A patent/EA200702419A1/en unknown
- 2006-05-04 KR KR1020077028300A patent/KR20080021636A/en not_active Application Discontinuation
- 2006-05-04 AP AP2007004227A patent/AP2007004227A0/en unknown
- 2006-05-04 BR BRPI0612471A patent/BRPI0612471A2/en not_active IP Right Cessation
- 2006-05-04 JP JP2008509578A patent/JP2008540402A/en not_active Withdrawn
- 2006-05-04 CA CA002606894A patent/CA2606894A1/en not_active Abandoned
-
2007
- 2007-11-01 IL IL187105A patent/IL187105A0/en unknown
- 2007-11-06 NO NO20075618A patent/NO20075618L/en not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
WO2002028438A1 (en) * | 2000-10-05 | 2002-04-11 | King's College London | Lipopeptides as absorption enhancers for bioactive compounds |
WO2003011892A2 (en) * | 2001-07-31 | 2003-02-13 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1 exendin-4 peptide analogs and uses thereof |
WO2003058203A2 (en) * | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
WO2004094461A2 (en) * | 2003-04-21 | 2004-11-04 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
WO2005077072A2 (en) * | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2006014287A1 (en) * | 2004-07-02 | 2006-02-09 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
WO2006024275A2 (en) * | 2004-09-03 | 2006-03-09 | Philipps-Universität Marburg | Glp-1 and exendin related invention |
Non-Patent Citations (7)
Title |
---|
AL-SABAH SULEIMAN ET AL: "A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 140, no. 2, September 2003 (2003-09-01), pages 339 - 346, XP002437826, ISSN: 0007-1188 * |
CHAHRZAD MONTROSE-RAFIZADEH ET AL: "High Potency Antagonists of the Pancreatic Glucagon-like Peptide-1 Receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 272, no. 34, 22 August 1997 (1997-08-22), pages 21201 - 21206, XP002247450, ISSN: 0021-9258 * |
DOYLE MAIRE E ET AL: "The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity.", REGULATORY PEPTIDES, vol. 114, no. 2-3, 15 July 2003 (2003-07-15), pages 153 - 158, XP002441636, ISSN: 0167-0115 * |
GREEN B D ET AL: "STRUCTURALLY MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AND GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) AS FUTURE ANTIDIABETIC AGENTS", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 10, no. 29, 2004, pages 3651 - 3662, XP009068381, ISSN: 1381-6128 * |
HINKE SIMON A ET AL: "In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 75, no. 15, 27 August 2004 (2004-08-27), pages 1857 - 1870, XP002387302, ISSN: 0024-3205 * |
RUNGE S ET AL: "Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity.", BRITISH JOURNAL OF PHARMACOLOGY, vol. 138, no. 5, March 2003 (2003-03-01), pages 787 - 794, XP002427759, ISSN: 0007-1188 * |
XIAO Q ET AL: "Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 40, no. 9, 6 March 2001 (2001-03-06), pages 2860 - 2869, XP002277645, ISSN: 0006-2960 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007017892A2 (en) | 2007-02-15 |
NO20075618L (en) | 2008-01-30 |
AP2007004227A0 (en) | 2007-12-31 |
EP1891106A2 (en) | 2008-02-27 |
EA200702419A1 (en) | 2008-04-28 |
CA2606894A1 (en) | 2007-02-15 |
AU2006277557A1 (en) | 2007-02-15 |
IL187105A0 (en) | 2008-02-09 |
BRPI0612471A2 (en) | 2016-09-06 |
JP2008540402A (en) | 2008-11-20 |
KR20080021636A (en) | 2008-03-07 |
MX2007013655A (en) | 2008-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007017892A3 (en) | Novel compounds as glp-i agonists | |
WO2007085895A3 (en) | Fap inhibitors | |
CR9369A (en) | ACETIC ACID PERIDIL COMPOUNDS | |
AU2008303600A8 (en) | 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives | |
MX2007014172A (en) | Processes for production of phenolic 4-biphenylylazetidin-2-ones. | |
WO2008083248A3 (en) | Cyclopamine analogs | |
WO2009030469A8 (en) | Fungicidal 2-alkylthio-2-quinolinyloxy-acetamide deritvatives | |
GB0521508D0 (en) | Organic compounds | |
EP2677562A3 (en) | Arylamines for organic electroluminescent devices | |
WO2009156462A3 (en) | Organic compounds | |
WO2007031548A3 (en) | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | |
WO2009146218A8 (en) | Compounds including an anti-inflammatory pharmacore and methods of use | |
WO2007003962A3 (en) | Gpcr agonists | |
WO2007003961A3 (en) | Gpcr agonists | |
WO2009019015A8 (en) | Novel herbicides | |
WO2009049716A3 (en) | Novel fungicides | |
WO2008059370A3 (en) | Substituted bicyclocarboxyamide compounds | |
WO2009121939A3 (en) | C-aryl glycoside compounds for the treatment of diabetes and obesity | |
MX2010004669A (en) | Preparation of dihydropyrrol derivatives as intermediates. | |
MX2009008660A (en) | Method for the preparation of therapeutically valuable triphenylbutene derivatives. | |
WO2008151828A3 (en) | Novel microbiocides | |
WO2009127718A3 (en) | Novel microbiocides | |
ATE417849T1 (en) | PYRAZOLOA4,3-DÜPYRIMIDINE | |
WO2009000533A8 (en) | Novel herbicides | |
MX2009004991A (en) | Cyclopentene diol monoacetate derivatives. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/013655 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 187105 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008509578 Country of ref document: JP Ref document number: 12007502447 Country of ref document: PH Ref document number: 2606894 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006809915 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006277557 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07121830 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2006277557 Country of ref document: AU Date of ref document: 20060504 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006277557 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077028300 Country of ref document: KR Ref document number: 200702419 Country of ref document: EA |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 564030 Country of ref document: NZ Ref document number: 1200702605 Country of ref document: VN |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: RU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06809915 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680024277.1 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006809915 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0612471 Country of ref document: BR Kind code of ref document: A2 Effective date: 20071105 |